<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539496</url>
  </required_header>
  <id_info>
    <org_study_id>XZP-3287-1001</org_study_id>
    <nct_id>NCT04539496</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors</brief_title>
  <official_title>A Multicenter, Open-label Phase I/II Study of XZP-3287 in Metastasis Solid Tumors in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sihuan Pharmaceutical Holdings Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sihuan Pharmaceutical Holdings Group Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study includes Single agent/combination dose exploration study and the phase II study.&#xD;
      The primary purpose of this study is to determine the maximum tolerated dose(MTD)/recommended&#xD;
      phase II dose(RP2D) of XZP-3287 and its efficacy and safety in hormone receptor(HR) positive,&#xD;
      human epidermal growth factor receptor 2(HER2) negative advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single agent and combination dose exploration study：safety</measure>
    <time_frame>Baseline up to 1 year</time_frame>
    <description>Maximum tolerated dose of XZP-3287</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the phase II study：Objective response rate (ORR)</measure>
    <time_frame>Baseline up to 1 year</time_frame>
    <description>ORR is the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) as defined by RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>Baseline up to 1 year</time_frame>
    <description>PFS is defined as the time from the date of the first treatment until first observation of objective progressive disease or death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>Baseline up to 5 years</time_frame>
    <description>OS is defined from the date of the first treatment to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DoR)</measure>
    <time_frame>Baseline up to 1 year</time_frame>
    <description>DoR is defined from the date of CR or PR to date of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Baseline up to 1 year</time_frame>
    <description>DCR is the percentage of participants with a best overall response of CR, PR or stable disease (SD) as defined by RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical benefit rate (CBR)</measure>
    <time_frame>Baseline up to 1 year</time_frame>
    <description>Percentage of participants with best overall response of CR, PR, or SD with duration of SD for at least 6 Months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics (PK)</measure>
    <time_frame>Baseline up to month 3</time_frame>
    <description>Mean steady state exposure of XZP-3287 and its metabolites.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Metastasis Solid Tumors</condition>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>dose confirmation and the phase II study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the MTD and RP2D of XZP-3287; To determine the RP2D of XZP-3287 combined with endocrine therapy; To determine the efficacy and safety of XZP-3287 in HR positive HER2 negative advanced breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-3287</intervention_name>
    <description>a small molecular, oral potent, selective CDK4/6 inhibitor</description>
    <arm_group_label>dose confirmation and the phase II study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Single agent and combination dose exploration study：Patient is an adult male/female&#xD;
             18~70 years old; the phase II study：Patient is an adult male/female ≥ 18 years old;&#xD;
&#xD;
          -  Single agent dose escalation study ：Patients with a histologically or cytologically&#xD;
             confirmed diagnosis of a solid tumor for which Standard treatment failure or no&#xD;
             further effective standard treatment is available.&#xD;
&#xD;
        Combination dose exploration study：Patients with locally advanced or metastatic breast&#xD;
        cancer with hormone receptor positive (HR+) and her2-negative (HER2-) were not eligible for&#xD;
        surgical resection or radiotherapy for the purpose of cure, and had no clinical indications&#xD;
        for chemotherapy, and received endocrine therapy ≤1 line.&#xD;
&#xD;
        The phase II study: Locally advanced or metastatic breast cancer diagnosed histologically&#xD;
        or cytologically not suitable for surgery or radical radiotherapy; HR+ and HER2- ; have&#xD;
        locally advanced disease not amenable to curative treatment by surgery or metastatic&#xD;
        disease; progress after previous endocrine therapy; at least 1 chemotherapy regimen in the&#xD;
        previous adjuvant or metastasis contains paclitaxel or capecitabine; there should be no&#xD;
        more than 2 chemotherapy regimens in the recurrent or metastatic stage;&#xD;
&#xD;
          -  At least one measurable lesion (based on RECIST v1.1);&#xD;
&#xD;
          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;&#xD;
&#xD;
          -  Have recovered from the acute effects of therapy (until the toxicity resolves to&#xD;
             either baseline or Grade 1) except for residual alopecia;&#xD;
&#xD;
          -  Adequate organ and marrow function;&#xD;
&#xD;
          -  The life expectancy of the patient was determined by the investigator to be ≥12 weeks;&#xD;
&#xD;
          -  Fertile male or female patients must agree to use an effective contraceptive method&#xD;
             during the study period and for three months after the last study medication;&#xD;
&#xD;
          -  Patient has signed informed consent before any trial related activities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Single agent and combination dose exploration study：Patients with known uncontrolled&#xD;
             or symptomatic CNS metastases; The phase II study：Have central nervous system (CNS)&#xD;
             metastasis, or Have visceral crisis, or Inflammatory breast cancer.&#xD;
&#xD;
          -  Have received an autologous or allogeneic stem-cell transplant.&#xD;
&#xD;
          -  Patient has impairment of gastrointestinal (GI) function or GI disease.&#xD;
&#xD;
          -  Single agent and combination dose exploration study：Any other malignancy was diagnosed&#xD;
             within 3 years prior to enrollment, except for basal cell carcinoma, squamous cell&#xD;
             carcinoma, or carcinoma in situ of the cervix, which is adequately treated and the&#xD;
             disease is stable.&#xD;
&#xD;
        The phase II study：Have a history of any other cancer (except nonmelanoma skin cancer or&#xD;
        carcinoma in-situ of the cervix), unless in complete remission with no therapy for a&#xD;
        minimum of 3 years.&#xD;
&#xD;
          -  Subject has impaired cardiac function or heart disease of clinical significance.&#xD;
&#xD;
          -  Cerebrovascular accidents within 6 months before enrollment, including a history of&#xD;
             transient ischemic attack or stroke.&#xD;
&#xD;
          -  Major surgery or surgical treatment due to any cause occurred within 4 weeks prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Presence of any serious and/or uncontrolled disease in the opinion of the investigator&#xD;
             that may interfere with the study assessment.&#xD;
&#xD;
          -  Uncontrollable pleural effusion, peritoneal effusion, pericardial effusion in the 4&#xD;
             weeks before the first administration (except for a small amount of effusion detected&#xD;
             by imaging examination).&#xD;
&#xD;
          -  A prior history of definite neurological or psychiatric disorders, including epilepsy&#xD;
             or dementia.&#xD;
&#xD;
          -  Chronic active HBV, HCV or HIV diseases.&#xD;
&#xD;
          -  Patient who received any CDK4/6 inhibitor or patients who plan surgery, or the&#xD;
             investigator determines that surgery or radical radiation therapy is required.&#xD;
&#xD;
          -  Participation in a prior treatment of chemotherapy, radiotherapy, endocrinotherapy,&#xD;
             targeted therapy, immunotherapy and any investigational study within 14 days prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Bone marrow suppression therapy, such as GCS-F, EPO, or blood transfusion, was&#xD;
             administered within 14 days prior to enrollment.&#xD;
&#xD;
          -  Patient with a known hypersensitivity to any of the excipients in this study.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  The researchers considered that there were some cases that were not suitable for&#xD;
             inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Binghe Xu, Doctor</last_name>
    <phone>(+86)(10)(87788826)</phone>
    <email>xubinghe@csco.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binghe Xu, Doctor</last_name>
      <phone>(+86)(10)(87788826)</phone>
      <email>xubinghe@csco.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

